Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The ucla experience

✍ Scribed by Jeffrey D. Lee; Sol Perez; He-Jing Wang; Robert A. Figlin; Dr. E. Carmack Holmes

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 537 KB
• Volume: 60
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930600410

✦ Synopsis

From 1986 to 1993, 15 patients with malignant pleural mesothelioma were treated by pleurectomy/decortication and intrapleural cisplatin ( 100 mg/ m2) and cytosine arabinoside (1,200 mg). All patients were without known extrathoracic disease and had a mean age of 63.5 k 7.9 years (range 51-78); 13 were male. Histologic subtype of disease were epithelial (47%), sarcomatoid (27%), and mixed-biphasic (27%). The major morbidity and mortality rates were 13% and 0%, respectively. The mean length of hospital stay was 6.5 k 2.1 days. Postoperatively, adjuvant chemotherapy and radiation therapy were given to 46% and 73% of the patients respectively. Median survival from date of treatment was 11.5 months. Those patients with an epithelial histologic subtype experienced significantly improved survival compared to those of sarcomatoid subtype (P = 0.024). Whether adjuvant chemotherapy or radiation therapy were given had no significant effect on survival. These data suggest that although this treatment regimen can be administered with very limited morbidity and no mortality, the role of this approach in the treatment of malignant pleural mesothelioma appears limited and cannot currently be recommended.